Big news for the world of healthcare tech! Quibim, a Spanish startup focused on using AI for medical imaging, just scored $50 million in a Series A funding round. Their goal? To make diagnosing diseases like cancer faster, more accurate, and way more effective.

Quibim’s tech works with X-rays, CT scans, and MRIs to spot issues in organs like the brain, liver, and prostate. Their star product, QP-Prostate, is already making waves in detecting prostate cancer. And they’re not stopping there—similar tools are in the works for other parts of the body.

But that’s not all. The company also has QP-Insights, a platform for analyzing different types of biological data, which could be a game-changer for clinical trials. Looking further ahead, Quibim dreams of creating digital twins of the entire human body. Think of it as a high-tech map that helps doctors understand and treat diseases better.

This fresh funding isn’t just about research, though. Quibim is setting its sights on the U.S. market. They’ve already got FDA clearance for QP-Prostate and are ramping up their presence stateside. Plus, they’re teaming up with big names like Stanford University and Mass General Brigham, not to mention integrating their AI with Philips’ medical scanners.

The Series A round was led by Spanish firms Asabys and Buenavista, with some notable backers like Amadeus Capital Partners and Tony Fadell, the co-creator of the iPod.

“Our mission is to use imaging to transform healthcare,” said Quibim’s CEO, Ángel Alberich-Bayarri. “Expanding into the U.S. is a huge step forward in making this vision a reality.”

With 170 installations worldwide and big plans on the horizon, Quibim is definitely one to watch in the AI healthcare space. Keep an eye out—this could change the way we think about medical diagnostics forever.